No

Analgesic, Narcotic

Relief of moderate to severe postoperative, acute renal and ureteral colic, and cancer pain

C

Patients experiencing immediate type hypersensitivity reactions (anaphylaxis) to dezocine or structurally related compounds should not receive this drug. Use of other central nervous system depressants concurrently to dezocine is contraindicated.

Use with caution in patients with head injuries or increased intracranial pressure, respiratory depression, asthma, emphysema, COPD, renal or hepatic disease, labor and delivery, biliary surgery, or in patients with a history of drug abuse; abuse potential is apparent; may be better tolerated than other opioid agonist-antagonist; does not affect cardiac performance; contains bisulfites, avoid use in those sensitive to bisulfites

1% to 10%:

Central nervous system: Sedation, dizziness, vertigo

Gastrointestinal: Nausea, vomiting

Local: Injection site reactions

<1%: Hypotension, palpitations, bradycardia, peripheral vasodilation, increased intracranial pressure, CNS depression, drowsiness, antidiuretic hormone release, constipation, biliary tract spasm, urinary tract spasm, miosis, respiratory depression, histamine release, physical and psychological dependence with prolonged use

Symptoms of overdose include CNS and respiratory depression, gastrointestinal cramping, constipation

Naloxone 2 mg I.V. (0.01 mg/kg for children) with repeat administration as necessary up to a total of 10 mg

Increased effect with CNS depressants

Store at room temperature; protect from light

Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression; it is a mixed agonist-antagonist that appears to bind selectively to CNS m and D opiate receptors

Onset of analgesia: Within 15-30 minutes

Peak effect: 1 hour

Duration of analgesia: 4-6 hours

Half-life: 2.6-2.8 hours

Metabolism: Glucuronidated in liver

Elimination: Excretion of inactive metabolites and unchanged drug in the urine

Adults (not recommended for patients <18 years):

I.V.: Initial: 2.5-10 mg; may be repeated every 2-4 hours as needed

Dosing adjustment in renal impairment: Should be used cautiously at reduced doses

Monitor blood pressure and heart rate during adjustment of dose

Sedation is common; may see depression

Contraindicated with other CNS depressants

No information available to require special precautions

No effects or complications reported

Avoid driving or operating machinery until the effect of drug wears off; may cause physical and psychological dependence with prolonged use

Watch closely for respiratory depression; induced respiratory depression is greater than that seen with morphine during the first hour after administration

Injection, single-dose vial: 5 mg/mL (2 mL); 10 mg/mL (2 mL); 15 mg/mL (2 mL)

"Drugs for Pain," Med Lett Drugs Ther, 1998, 40(1033):79-84.